Table 1. Baseline Characteristics of the Population Included in the Study.
| Characteristic | Exposure Group, No. (%) | |
|---|---|---|
| Non–PPI Users (n = 626 887) | Continuous PPI Users (n = 233 596) | |
| Age, median (interquartile range), y | 70 (61-80) | 71 (62-81) |
| Age group, y | ||
| 0-4 | 659 (0.1) | 239 (0.1) |
| 5-14 | 338 (0.1) | 141 (0.1) |
| 15-44 | 25 648 (4.1) | 9788 (4.2) |
| 45-64 | 181 536 (29.0) | 63 984 (27.4) |
| 65-74 | 182 984 (29.2) | 64 721 (27.7) |
| ≥75 | 235 722 (37.6) | 94 723 (40.5) |
| Sex | ||
| Female | 353 128 (56.3) | 130 285 (55.8) |
| Male | 273 759 (43.7) | 103 311 (44.2) |
| Treatments for chronic conditions | ||
| Cardiovascular diseases | 433 357 (69.1) | 188 379 (80.6) |
| Diabetes | 92 335 (14.7) | 45 788 (19.6) |
| Psychiatric diseases | 197 478 (31.5) | 116 873 (50.0) |
| Obstructive airway diseases | 71 574 (11.4) | 46 946 (20.1) |
Abbreviation: PPI, proton pump inhibitor.